Proton MR Spectroscopy–Detectable Major Neurotransmitters of the Brain: Biology and Possible Clinical Applications

References

1. 1.↵
   1. Braitenberg V,
   2. Schüz A

   . Cortex: Statistics and Geometry of Neuronal Connectivity. Berlin, Germany: Springer-Verlag; 1998
2. 2.↵
   1. Shen J,
   2. Petersen KF,
   3. Behar KL,
   4. et al

   . Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci U S A 1999;96: 8235–40

   Abstract/FREE Full Text
3. 3.↵
   1. Attwell D,
   2. Laughlin SB

   . An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 2001;21: 1133–45

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Pellerin L,
   2. Magistretti PJ

   . Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 1994;91: 10625–29

   Abstract/FREE Full Text
5. 5.↵
   1. Sibson NR,
   2. Dhankhar A,
   3. Mason GF,
   4. et al

   . Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci U S A 1998;95: 316–21

   Abstract/FREE Full Text
6. 6.↵
   1. van den Berg CJ,
   2. Garfinkel D

   . A simulation study of brain compartments: metabolism of glutamate and related substances in mouse brain. Biochem J 1971;123: 211–18

   Abstract/FREE Full Text
7. 7.↵
   1. Pellerin L,
   2. Bouzier-Sore AK,
   3. Aubert A,
   4. et al

   . Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 2007;55: 1251–62

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Conn PJ,
   2. Pin JP

   . Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37: 205–37

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Corti C,
   2. Battaglia G,
   3. Molinaro G,
   4. et al

   . The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci 2007;27: 8297–308

   Abstract/FREE Full Text
10. 10.↵
    1. Kvamme E,
    2. Schousboe A,
    3. Hertz L,
    4. et al

    . Developmental change of endogenous glutamate and gamma-glutamyl transferase in cultured cerebral cortical interneurons and cerebellar granule cells, and in mouse cerebral cortex and cerebellum in vivo. Neurochem Res 1985;10: 993–1008

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Beart PM,
    2. O'Shea RD

    . Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol 2007;150: 5–17

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Esclapez M,
    2. Tillakaratne NJ,
    3. Kaufman DL,
    4. et al

    . Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci 1994;14: 1834–55

    Abstract
13. 13.↵
    1. Wu H,
    2. Jin Y,
    3. Buddhala C,
    4. et al

    . Role of glutamate decarboxylase (GAD) isoform, GAD65, in GABA synthesis and transport into synaptic vesicles: evidence from GAD65-knockout mice studies. Brain Res 2007;1154: 80–83

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Martin DL,
    2. Rimvall K

    . Regulation of gamma-aminobutyric acid synthesis in the brain. J Neurochem 1993;60: 395–407

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Gadea A,
    2. Lopez-Colome AM

    . Glial transporters for glutamate, glycine, and GABA. II. GABA transporters. J Neurosci Res 2001;63: 461–68

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Chatton JY,
    2. Pellerin L,
    3. Magistretti PJ

    . GABA uptake into astrocytes is not associated with significant metabolic cost: implications for brain imaging of inhibitory transmission. Proc Natl Acad Sci U S A 2003;100: 12456–61

    Abstract/FREE Full Text
17. 17.↵
    1. Cherubini E,
    2. Conti F

    . Generating diversity at GABAergic synapses. Trends Neurosci 2001;24: 155–62

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Pouwels PJ,
    2. Frahm J

    . Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed 1997;10: 73–78

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Gehl LM,
    2. Saab OH,
    3. Bzdega T,
    4. et al

    . Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia. J Neurochem 2004;90: 989–97

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Wroblewska B,
    2. Santi MR,
    3. Neale JH

    . N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 1998;24: 172–79

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Bergeron R,
    2. Coyle JT,
    3. Tsai G,
    4. et al

    . NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 2005;30: 7–16

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Baslow MH

    . The astrocyte surface NAAG receptor and NAAG peptidase signaling complex as a therapeutic target. Drug News Perspect 2008;21: 251–57

    CrossRefPubMed
23. 23.↵
    1. Baslow MH,
    2. Guilfoyle DN

    . Using proton magnetic resonance imaging and spectroscopy to understand brain “activation.” Brain Lang 2007;102: 153–64

    CrossRefPubMed
24. 24.↵
    1. Baslow MH,
    2. Dyakin VV,
    3. Nowak KL,
    4. et al

    . 2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia. J Mol Neurosci 2005;26: 1–15

    CrossRefPubMed
25. 25.↵
    1. Hayashi T

    . A physiological study of epileptic seizures following cortical stimulation in animals and its application to human clinics. Jpn J Physiol 1952;3: 46–64

    CrossRefPubMed
26. 26.↵
    1. Chapman AG

    . Glutamate and epilepsy. J Nutr 2000;130: 1043S–45S

    PubMedWeb of Science
27. 27.↵
    1. Jabs R,
    2. Seifert G,
    3. Steinhauser C

    . Astrocytic function and its alteration in the epileptic brain. Epilepsia 2008;49 (suppl 2): 3–12
28. 28.↵
    1. la Fougere C,
    2. Rominger A,
    3. Forster S,
    4. et al

    . PET and SPECT in epilepsy: a critical review. Epilepsy Behav 2009;15: 50–55. Epub 2009 Feb 21

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Pfund Z,
    2. Chugani DC,
    3. Juhasz C,
    4. et al

    . Evidence for coupling between glucose metabolism and glutamate cycling using FDG PET and 1H magnetic resonance spectroscopy in patients with epilepsy. J Cereb Blood Flow Metab 2000;20: 871–78

    PubMedWeb of Science
30. 30.↵
    1. White HS,
    2. Smith MD,
    3. Wilcox KS

    . Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007;81: 85–110

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Pacheco Otalora LF,
    2. Moffett JR,
    3. Garrido-Sanabria ER

    . Selective vulnerability of hippocampal NAAGergic neurons in experimental temporal lobe epilepsy. Brain Res 2007;1144: 219–30

    CrossRefPubMed
32. 32.↵
    1. Meyerhoff JL,
    2. Carter RE,
    3. Yourick DL,
    4. et al

    . Activity of a NAAG-hydrolyzing enzyme in brain may affect seizure susceptibility in genetically epilepsy-prone rats. Epilepsy Res Suppl 1992;9: 163–72

    PubMed
33. 33.↵
    1. Petroff OA,
    2. Rothman DL,
    3. Behar KL,
    4. et al

    . Low brain GABA level is associated with poor seizure control. Ann Neurol 1996;40: 908–11

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Petroff OA,
    2. Hyder F,
    3. Collins T,
    4. et al

    . Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia 1999;40: 958–64

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Woermann FG,
    2. McLean MA,
    3. Bartlett PA,
    4. et al

    . Short echo time single-voxel 1H magnetic resonance spectroscopy in magnetic resonance imaging-negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Ann Neurol 1999;45: 369–76

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Simister RJ,
    2. McLean MA,
    3. Barker GJ,
    4. et al

    . Proton MR spectroscopy of metabolite concentrations in temporal lobe epilepsy and effect of temporal lobe resection. Epilepsy Res 2009;83: 168–76

    CrossRefPubMed
37. 37.↵
    1. Ulu MO,
    2. Tanriverdi T,
    3. Oz B,
    4. et al

    . The expression of astroglial glutamate transporters in patients with focal cortical dysplasia: an immunohistochemical study. Acta Neurochir (Wien) 2010;152: 845–53. Epub 2009 Oct 27

    CrossRefPubMed
38. 38.↵
    1. Provencher SW

    . Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30: 672–9

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Aggarwal S,
    2. Cudkowicz M

    . ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008;5: 516–27

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Choi JK,
    2. Kustermann E,
    3. Dedeoglu A,
    4. et al

    . Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur J Neurosci 2009;30: 2143–50. Epub 2009 Nov 20

    CrossRefPubMed
41. 41.↵
    1. Han J,
    2. Ma L

    . Study of the features of proton MR spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis. J Magn Reson Imaging 2010;31: 305–08

    CrossRefPubMed
42. 42.↵
    1. Boillee S,
    2. Vande Velde C,
    3. Cleveland DW

    . ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006;52: 39–59

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Rothstein JD,
    2. Tsai G,
    3. Kuncl RW,
    4. et al

    . Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28: 18–25

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Tsai GC,
    2. Stauch-Slusher B,
    3. Sim L,
    4. et al

    . Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Res 1991;556: 151–56

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Rupsingh R,
    2. Borrie M,
    3. Smith M,
    4. et al

    . Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 2011;32: 802–10. Epub 2009 Jun 6

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Marjanska M,
    2. Curran GL,
    3. Wengenack TM,
    4. et al

    . Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 2005;102: 11906–10

    Abstract/FREE Full Text
47. 47.↵
    1. Glodzik L,
    2. King KG,
    3. Gonen O,
    4. et al

    . Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 1005–12

    CrossRefPubMed
48. 48.↵
    1. Penner J,
    2. Rupsingh R,
    3. Smith M,
    4. et al

    . Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 2010;34: 104–10

    CrossRefPubMed
49. 49.↵
    1. Griffith HR,
    2. den Hollander JA,
    3. Okonkwo OC,
    4. et al

    . Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement 2008;4: 421–27

    CrossRefPubMed
50. 50.↵
    1. Tkac I,
    2. Dubinsky JM,
    3. Keene CD,
    4. et al

    . Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. J Neurochem 2007;100: 1397–406. Epub 2007 Jan 8

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Reynolds NC,
    2. Prost RW,
    3. Mark LP,
    4. et al

    . MR-spectroscopic findings in juvenile-onset Huntington's disease. Mov Disord 2008;23: 1931–35

    CrossRefPubMed
52. 52.↵
    1. Theberge J,
    2. Williamson KE,
    3. Aoyama N,
    4. et al

    . Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007;191: 325–34

    Abstract/FREE Full Text
53. 53.↵
    1. Agarwal N,
    2. Port JD,
    3. Bazzocchi M,
    4. et al

    . Update on the use of MR for assessment and diagnosis of psychiatric diseases. Radiology 2010;255: 23–41

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Epperson CN,
    2. Gueorguieva R,
    3. Czarkowski KA,
    4. et al

    . Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Berl) 2006;186: 425–33

    CrossRefPubMed
55. 55.↵
    1. DeVito TJ,
    2. Drost DJ,
    3. Pavlosky W,
    4. et al

    . Brain magnetic resonance spectroscopy in Tourette's disorder. J Am Acad Child Adolesc Psychiatry 2005;44: 1301–08

    CrossRefPubMedWeb of Science
56. 56.↵
    1. Kickler N,
    2. Krack P,
    3. Fraix V,
    4. et al

    . Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. NMR Biomed 2007;20: 757–62

    CrossRefPubMed
57. 57.↵
    1. Bogner W,
    2. Gruber S,
    3. Doelken M,
    4. et al

    . In vivo quantification of intracerebral GABA by single-voxel (1)H-MRS: how reproducible are the results? Eur J Radiol 2010;73: 526–31

    CrossRefPubMed
58. 58.↵
    1. Provencher SW,
    2. Hänicke W,
    3. Michaelis T

    . Automated quantitation of localized 1H MR spectra in vivo: capabilities and limitations. In: Proceedings of the Third Scientific Meeting of the Society of Magnetic Resonance, Nice, France; August 19–25, 1995
59. 59.
    1. Simister RJ,
    2. McLean MA,
    3. Barker GJ,
    4. et al

    . MRS reveals frontal lobe metabolite abnormalities in idiopathic generalized epilepsy. Neurology 2003;61: 897–902

    Abstract/FREE Full Text
60. 60.
    1. Taki MM,
    2. Harada M,
    3. Mori K,
    4. et al

    . High gamma-aminobutyric acid level in cortical tubers in epileptic infants with tuberous sclerosis complex measured with the MEGA-editing J-difference method and a three-Tesla clinical MRI instrument. Neuroimage 2009;47: 1207–14

    CrossRefPubMedWeb of Science
61. 61.
    1. Stagg CJ,
    2. Lang B,
    3. Best JG,
    4. et al

    . Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia 2010;51: 1898–901

    CrossRefPubMedWeb of Science
62. 62.
    1. Simister RJ,
    2. Mclean MA,
    3. Barker GJ,
    4. et al

    . Proton magnetic resonance spectroscopy of malformations of cortical development causing epilepsy. Epilepsy Res 2007;74: 107–15

    CrossRefPubMedWeb of Science
63. 63.
    1. Lin K,
    2. Carrete H Jr.,
    3. Lin J,
    4. et al

    . Magnetic resonance spectroscopy reveals an epileptic network in juvenile myoclonic epilepsy. Epilepsia 2009;60: 1191–2000
64. 64.
    1. Doelken MT,
    2. Hammen T,
    3. Bogner W,
    4. et al

    . Alterations of intracerebral γ-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies. Epilepsia 2010;51: 1477–82

    CrossRefPubMed
65. 65.
    1. Mueller SG,
    2. Weber OM,
    3. Duc CO,
    4. et al

    . Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. Epilepsia 2001;42: 29–40
66. 66.
    1. Petroff OA,
    2. Hyder F,
    3. Rothman DL,
    4. et al

    . Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia 2001;42: 543–48

    CrossRefPubMedWeb of Science
67. 67.
    1. Rijpkema M,
    2. Schuuring J,
    3. van der Meulen Y,
    4. et al

    . Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003;16: 12–18

    CrossRefPubMedWeb of Science
68. 68.
    1. Prescot A,
    2. Becerra L,
    3. Pendse G,
    4. et al

    . Excitatory neurotransmitters in brain regions in interictal migrane patients. Mol Pain 2009;5: 34
69. 69.
    1. Antuono PG,
    2. Jones JL,
    3. Wang Y,
    4. et al

    . Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology 2001;56: 737–42

    Abstract/FREE Full Text
70. 70.
    1. Hattori N,
    2. Abe K,
    3. Sakoda S,
    4. et al

    . Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002;13: 183–86

    CrossRefPubMedWeb of Science
71. 71.
    1. Glodzik L,
    2. King KG,
    3. Gonen O,
    4. et al

    . Memantine decreases hippocampal glutamate level: a magnetic resonance spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 1005–12

    CrossRefPubMed
72. 72.
    1. Oz G,
    2. Terpstra M,
    3. Tkác I,
    4. et al

    . Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 2006;55: 296–301

    CrossRefPubMed